This summer, Station Houston is connecting the dots for student and alumni entrepreneurs within Houston's innovation ecosystem. Station Houston/Facebook

Houston universities — namely the University of Houston and Rice University — have been providing student and alumni entrepreneurs with acceleration programming for some time now through RED Labs and OwlSpark, respectively. But nonprofit acceleration hub Station Houston is connecting the dots with these programs — and inviting more schools to join in — through a new summer acceleration program.

"One of the things we haven't historically had in Houston that other cities have are broad collaborations between our universities to help build on one another's resources and really demonstrate for our young people — the talent that we want to keep here — exactly how deep and strong the opportunity to be in Houston is," Gabriella Rowe, CEO of Station, tells InnovationMap.

The program will bring in 30 to 40 student and alumni from academic partners, which currently includes Rice, UH, and the University of St. Thomas, to Station. The schools will be responsible for selecting their participants and some of their own programming, and Station will provide additional resources, events, and full member access.

"We're not just going to depend on them bumping into someone at the coffee pot," Rowe says. "We're going to do meet and greets, some speed dating events, and some pitch practice events, so that they have the opportunity to have experienced entrepreneurs give them feedback and share their experiences."

The program, which is free to its participants, has derived out of planning for the Rice University's upcoming innovation district hub called The Ion, for which Station is the programming partner. Launching the student and alumni summer program ahead of The Ion's debut allows Station to get a couple summer cohorts under its belt.

"We have been for a number of months now — and will continue for the next two years — built out out a hub where all of the things that can be happening in The Ion," Rowe says. "We're piloting an building here first, so that, when the building opens, it can open in full force."

The plan is also to collect more universities in the area for the program and even expand it to provide more student and alumni access to resources.

"We have the ability at Station to give an expanding base as more schools choose to join them over time, so that hopefully we end up with something that is really robust in its ability to support students all year round — not just as a summer program," Rowe says.

Combining the forces of Houston's universities is unprecedented, Rowe says, but crucial to ensuring that these young entrepreneurs aren't leaving Houston for other major cities unaware of what their city has out there for them.

"For me, more than anything, it's about exposing these young, motivated entrepreneurs to all of the resources available in Houston," Rowe says. "By bringing them here into Station, we have the ability to show them first hand what entrepreneurs in Houston have access to. It allows them to see what an incredible place Houston is to stay and build and grow your company."

The Ion is expected to debut in 2021. Courtesy of Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.